Movement Alert|PEGBIO CO-B Intraday Rise 7.08% in Regular Trading, Core Drug Entered the National Reimbursement Drug List

Market Focus11-16

On November 16, PEGBIO CO-B rose 7.08% in Regular Trading, trading at HK$3.38, with turnover of HK$50.10 million.

The move followed the company’s disclosure that its core product, Paidakang, or vebinatide injection, was included in the latest National Reimbursement Drug List, a milestone viewed by the market as supportive of commercialization.

The company said the drug is its first commercialized innovative therapy and has been approved for blood glucose control in adults with type 2 diabetes. Reported differentiating features include once-weekly dosing, treatment initiation without dose titration, and direct use from the start of therapy. The reimbursement listing is expected to improve patient access and support the transition from R&D to scaled commercialization. Earlier commercialization progress had already included first prescriptions and a milestone payment tied to launch execution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment